Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IoM finds no thimerosal link to autism

Executive Summary

Neither the measles-mumps-rubella vaccine nor thimerosal-containing vaccines are associated with autism, a May 17 Institute of Medicine report says. The 1report, "Immunization Safety Review: Vaccines and Autism," updates a 2001 report that found the link between thimerosal and neurodevelopmental disorders was unclear (2"The Pink Sheet" Oct. 8, 2001, p. 11). The latest report is based on "overwhelming evidence from several well-designed" clinical and epidemiological studies...

You may also be interested in...



Vaccine Safety Body Proposed To Remove FDA “Conflict Of Interest”

A proposal to move postmarket vaccine safety monitoring to an independent board outside FDA and CDC will be considered by the National Vaccine Advisory Committee at its next meeting

Thimerosal-Free Flu Vaccine Design Being Discussed By FDA, Manufacturers

FDA is discussing with manufacturers the development of influenza vaccines that have reduced thimerosal content or are thimerosal-free.

David Now Goliath? Made In China PD-1s Sought After By Multinationals

From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel